Bright Minds Biosciences Inc.
DRUG
CNSX
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 42.78% | 27.14% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | 200.43% | |||
| Total Operating Expenses | 15.04% | 92.26% | |||
| Operating Income | -15.04% | -92.26% | |||
| Income Before Tax | -82.94% | 21.72% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -82.94% | 21.72% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -82.94% | 21.72% | |||
| EBIT | -15.04% | -92.26% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -70.50% | 23.33% | |||
| Normalized Basic EPS | -70.50% | 23.33% | |||
| EPS Diluted | -69.17% | 22.73% | |||
| Normalized Diluted EPS | -70.50% | 23.33% | |||
| Average Basic Shares Outstanding | 7.30% | 2.11% | |||
| Average Diluted Shares Outstanding | 7.30% | 2.11% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||